Progenics Pharmaceuticals — Proxy Contest (June 2019)
58 slides from Progenics Pharmaceuticals's proxy contest presentation, Jun 20, 2019
Slide 1: Change is Necessary to Drive Long-Term Success at Progenics Pharmaceuticals, Inc.
Change is Necessary to Drive Long-Term Success at Progenics Pharmaceuticals, Inc. June 20, 2019 Velan Capital, L.P. – ALL RIGHTS RESERVED 1
Slide 2: Disclosure & Disclaimer
Disclosure & Disclaimer THIS PRESENTATION IS FOR DISCUSSION AND GENERAL INFORMATIONAL PURPOSES ONLY. IT DOES NOT HAVE REGARD TO THE SPECIFIC INVESTMENT OBJECTIVE, FINANCIAL SITUATION, SUITABILITY, OR THE PARTICULAR NEED OF ANY SPECIFIC PERSON WHO MAY RECEIVE THIS PRESENTATION, AND SHOULD NOT BE TAKE
Slide 3: Table of Contents
Table of Contents Executive Summary Performance, Stockholder & Governance Issues • Dismal Share Price Performance • Entrenchment-Minded Tactics & Egregious Governance Practices • Ineffective Oversight of Underqualified & Overpaid Management • Lack of Transparency Operational Concerns • Botched
Slide 4: Executive Summary
Executive Summary Velan Capital, L.P. – ALL RIGHTS RESERVED 4
Slide 5: This is a Rare Moment
This is a Rare Moment Stockholders have an opportunity to have their voices heard at the Progenics Pharmaceuticals, Inc. (“PGNX”, “Progenics”, or the “Company”) Annual Meeting to be held on Thursday, July 11th The Company’s slogan is “Find, Fight, and Follow” -- we urge stockholders to “Find” th
Slide 6: Situation Overview
Situation Overview Velan Capital, L.P. (“Velan Capital”), including the other participants in its call for change ("Velan", "Velan Group", or "we"), collectively own 9.3% of the outstanding shares of Progenics ― As the Company’s second largest stockholder, our goal is to maximize long-term value f
Slide 7: Introduction to Velan Capital
Introduction to Velan Capital Velan Capital is a private investment partnership that strives to optimize long-term value creation ― All of its capital comes from its principals (not passive investors) ― We are truly long-term owners and not agents Focus on undervalued healthcare companies with a
Slide 8: Progenics’ Board: An Ugly Report Card
Progenics’ Board: An Ugly Report Card Peter Crowley Michael Kishbauch (Chairman & (Chair of Nominating & Governance Mark Baker Committee & Member of (CEO & Director) Chair of Compensation Committee) Compensation Committee) Board Tenure 10+ years 5+ years ~10 years Total Stockholder Return (TSR) ~(45
Slide 9: Squandered Opportunities
Squandered Opportunities MIP-1095 MIP-1095 is a radiopharmaceutical that binds to prostate cancer cells to deliver highly targeted radiation MIP-1095 was acquired in January 2013 with strong clinical data already in hand ― MIP-1095 laid dormant and remained undeveloped by Progenics until the lic
Slide 10: Many Stockholders Share Velan’s Views
Many Stockholders Share Velan’s Views Numerous stockholders have reached out to Velan to express similar views and frustration regarding the Company’s lack of engagement and execution BOARD STRATEGY “The Board is truly a rubber stamp” “Never understood this company…have good assets but they don’t
Slide 11: Velan’s Rationale for Change
Velan’s Rationale for Change DISMAL SHARE PRICE PERFORMANCE GOVERNANCE ISSUES STOCKHOLDER & PERFORMANCE, ENTRENCHMENT-MINDED TACTICS & EGREGIOUS GOVERNANCE PRACTICES INEFFECTIVE OVERSIGHT OF UNDERQUALIFIED & OVERPAID MANAGEMENT LACK OF TRANSPARENCY BOTCHED COMMERCIAL EXECUTION OPERATIONAL CONCERNS Q
Slide 12: Performance, Stockholder & Governance Issues
Performance, Stockholder & Governance Issues Dismal Share Price Performance Velan Capital, L.P. – ALL RIGHTS RESERVED 12
Slide 13: Stock Price Reflects Poor Execution
Stock Price Reflects Poor Execution PGNX has underperformed on both an absolute and relative basis over almost any time period ― Since 2009: when Messrs. Crowley and Baker joined the Board ― Since 2013: when Mr. Kishbauch joined the Board ― In more recent years while AZEDRA approval and launch wer
Slide 14: Dramatic Relative Underperformance
Dramatic Relative Underperformance PERFORMANCE VS. INDICES SINCE 2009 600% NASDAQ Biotech Index (Total Return) 500% NASDAQ Composite (Total Return) 400% PGNX 300% 200% 100% 0% (100%) Jan-09 Jan-10 Jan-11 Jan-12 Jan-13 Jan-14 Jan-15 Jan-16 Jan-17 Jan-18 Jan-19 PERFORMANCE VS. ENDOCYTE SINCE LICENSE F
Slide 15: Weak Track Records In Other Roles As Well
Weak Track Records In Other Roles As Well Mr. Kishbauch has served on three other public company boards in the past ten years ― Achillion Pharmaceuticals, Inc. – appointed as director in July 2004 (served as President & CEO until May 2013) ― Catabasis Pharmaceuticals, Inc. – appointed as director
Slide 16: Exodus of Investors and Analysts
Exodus of Investors and Analysts Over the past five years, Progenics has had numerous notable healthcare investors exit their position ― 2015: Lord Abbett and Tiger Management ― 2016: Highbridge Capital ― 2017: Broadfin Capital and Wellington Management ― 2018: Baker Brothers, Fidelity Management
Slide 17: Entrenchment-Minded Tactics & Egregious Governance Practices
Performance, Stockholder & Governance Issues Entrenchment-Minded Tactics & Egregious Governance Practices Velan Capital, L.P. – ALL RIGHTS RESERVED 17
Slide 18: Velan’s Outreach to Progenics Repeatedly Dismissed
Velan’s Outreach to Progenics Repeatedly Dismissed In 2018 and early 2019, Velan reached out to Progenics management on multiple occasions ― After a telephonic meeting in November 2018 and an in-person meeting in January 2019, the Company went silent despite Velan’s continued outreach In Februar
Slide 19: Progenics’ Invalidation of Our Nomination
Progenics’ Invalidation of Our Nomination The Company’s Bylaws require that only stockholders of record may nominate director candidates On March 15, 2019, the date Velan submitted its nomination, it beneficially owned shares of Progenics in “street” name. While Velan is currently a stockholder
Slide 20: Minimal Board Alignment & Ownership
Minimal Board Alignment & Ownership Collectively, the non-executive directors own approximately 0.06% of Progenics common stock(1) Together, Messrs. Crowley and Kishbauch own ZERO shares of Progenics common stock(1) ― In 2018, Messrs. Crowley and Kishbauch earned $452,750 and $237,159, respectiv
Slide 21: Board is Stale and Has Not Fulfilled Duties
Board is Stale and Has Not Fulfilled Duties Stale Board in need of fresh perspectives, more relevant track records and stockholder alignment ― Approximately 50% of the non-executive directors on the Board have lengthy tenure (over 10-20+ years) ― Directors Crowley (Chairman) and Baker (CEO) have t
Slide 22: Ineffective Oversight of Underqualified & Overpaid Management
Performance, Stockholder & Governance Issues Ineffective Oversight of Underqualified & Overpaid Management Velan Capital, L.P. – ALL RIGHTS RESERVED 22
Slide 23: Ineffective Oversight of Unqualified Team
Ineffective Oversight of Unqualified Team Mark Baker’s biography ― “Mr. Baker, 63, Chief Executive Officer (“CEO”), joined us in 2005 as Senior Vice President & General Counsel and Secretary. In 2008, he was appointed Executive Vice President, Corporate, in 2009 became President and a director, an
Slide 24: Rewarding Perpetual Underperformance
Rewarding Perpetual Underperformance Board’s Assessment of Performance Recent Events Performance Goals in Velan’s Commentary Metric 2017 & 2018 AZEDRA is a highly valuable asset with AZEDRA PDUFA extended and potential to fill an unmet need for cancer subsequently approved in July 2018 patients
Slide 25: Board Appears to Value Pay Over Science
Board Appears to Value Pay Over Science Does the Board regard pay as a more pressing matter than scientific advancement and clinical success? ― In 2017, Progenics’ Compensation Committee met more often than the Scientific Committee ― In 2016, the Compensation Committee met twice as often as the Sc
Slide 26: Misaligned Compensation Program
Misaligned Compensation Program Under Mr. Crowley, as Chair of the Compensation Committee, and Mr. Kishbauch, as the only other member of the Compensation Committee, the Board has approved outsized pay while value has been destroyed, representing a clear misalignment of interests with stockholders
Slide 27: Annual Incentives are 100% Discretionary
Annual Incentives are 100% Discretionary The annual bonus is based on four metrics that are vague and entirely discretionary Each of the four targets required qualification from the Compensation Committee to justify payouts Even with the exclusion of an impairment charge related to failure of
Slide 28: Long-Term Incentives: 0% Performance-Based
Long-Term Incentives: 0% Performance-Based The Progenics Compensation Committee grants long-term incentive awards exclusively in the form of stock options without any performance-based conditions Most shareholders, and leading proxy advisers ISS and Glass Lewis, don’t consider options to be perf
Slide 29: Director Pay is Excessive and Egregious
Director Pay is Excessive and Egregious For 2018, the median of director pay at Progenics was $237,000, excluding Chairman Crowley, who received more than $452,000 in 2018 According to an ISS Board Practices Study in 2017, the median compensation for directors at Small Cap companies in the Pharm
Slide 30: Lack of Transparency
Performance, Stockholder & Governance Issues Lack of Transparency Velan Capital, L.P. – ALL RIGHTS RESERVED 30
Slide 31: AZEDRA’s Manufacturing Mystery
AZEDRA’s Manufacturing Mystery AZEDRA’s manufacturing situation appears fine per the risk disclosures in the Company’s 2018 10-K but physician feedback and two recent developments raise serious related concerns ― Manufacturing facility acquisition in February 2019 for $8 million ― Contract manufac
Slide 32: Lack of Regulatory Clarity
Lack of Regulatory Clarity Progenics has not been forthright with investors regarding the interactions with (and potential feedback from) the FDA on its Phase 2 clinical trial Progenics announced its decision to move MIP-1095 into Phase 2 trial in October 2018 Progress is needed but why make t
Slide 33: Velan’s Involvement Appears to be Making an Impact
Velan’s Involvement Appears to be Making an Impact We believe Velan’s call for transparency has led to improvements in Progenics’ June corporate presentation but much more clarity and information is needed Image Source: Company filings. Velan Capital, L.P. – ALL RIGHTS RESERVED 33
Slide 34: Operational Concerns: Botched Commercial Execution
Operational Concerns Botched Commercial Execution Velan Capital, L.P. – ALL RIGHTS RESERVED 34
Slide 35: Promises at Time of AZEDRA’s Approval
Promises at Time of AZEDRA’s Approval Upon its approval in July 2018, the Company stated that the nuclear, reimbursement and patient identification processes would take “weeks” not MORE THAN TEN MONTHS FDA APPROVAL PRESENTATION AND CONFERENCE CALL IN JULY 2018 “…I think you could view reimbursemen
Slide 36: Overpromised and Underdelivered
Overpromised and Underdelivered In July 2018, Progenics stated: ― AZEDRA was “ready for commercialization” ― Reimbursement should be a “smoother, quicker process” for centers that participated in the trial ― Patient identification and dosing should take “eight weeks” ― Nuclear process should take
Slide 37: AZEDRA: Comparison to Similar Products
AZEDRA: Comparison to Similar Products Progenics received approval for AZEDRA in July 2018 and dosed its first patient in June 2019 We could not find ONE other launch that took more than TEN MONTHS to dose a patient With no Orange Book patents, each day AZEDRA was delayed was a day lost of its
Slide 38: Physician Perspectives & Patient Impact
Physician Perspectives & Patient Impact Physician feedback regarding AZEDRA’s launch illustrates the lack of experience and oversight at Progenics ― Progenics even stated on its Q1 2019 earnings call “we're gaining experience with the drug” KOLs and physicians we spoke with heard from the Compan
Slide 39: Questionable Clinical Program Decision Making
Operational Concerns Questionable Clinical Program Decision Making Velan Capital, L.P. – ALL RIGHTS RESERVED 39
Slide 40: MIP-1095: Blind But Now I See
MIP-1095: Blind But Now I See In the six years since acquiring MIP-1095, arguably its most valuable asset, we believe the Board has shown continual neglect and a lack of urgency STANDING STILL AND WATCHING THE COMPETITION PASS BY It appears to have taken the foresight of Endocyte and its acquisi
Slide 41: AZEDRA: Advanced at Glacial Pace
AZEDRA: Advanced at Glacial Pace Progenics acquired AZEDRA from MIP in January 2013 ― In November 2013, Progenics announced it was “relaunching the registrational trial” ― In January 2015, Progenics noted that it had dosed the first subject since trial was resumed Similar to its commercial strug
Slide 42: Inefficient Financial Management
Operational Concerns Inefficient Financial Management Velan Capital, L.P. – ALL RIGHTS RESERVED 42
Slide 43: Poor Budget Containment / Enforcement
Poor Budget Containment / Enforcement The Company has not disclosed numerous financial details that we believe would help analysts and investors assess the Progenics opportunity and monitor performance However, based on available disclosures, we can symbolically observe wasteful spending For e
Slide 44: Capital Allocation Concerns
Capital Allocation Concerns In our meeting on March 25, 2019 with Messrs. Crowley and Baker, Mr. Baker launched into a series of flawed statements around the purported drawbacks of certain nondilutive financing alternatives and seemed to express a preference for extensive (and dilutive) equity off
Slide 45: Persistent & Unnecessary Dilution
Persistent & Unnecessary Dilution Since Chairman Crowley’s reign began in 2009, Progenics has completed equity financings raising more than $200 million, which currently represents over 50% of the Company’s fully-diluted equity value ― In 2018 alone, ~$100 million of dilutive equity was raised F
Slide 46: Conclusion
Conclusion Velan Capital, L.P. – ALL RIGHTS RESERVED 46
Slide 47: Now is the Time for Much Needed Change and Accountability at Progenics
Now is the Time for Much Needed Change and Accountability at Progenics We believe Progenics’ value resides primarily with its RELISTOR royalties, approved drug AZEDRA, net cash, and pipeline (particularly the 1095 and PyL programs) However, it is critical to efficiently direct appropriate resour
Slide 48: Your Choice and Voice Can Be Heard
Your Choice and Voice Can Be Heard We believe change is desperately needed at Progenics The first step toward achieving this change is by making your voices heard at the upcoming Annual Meeting by voting AGAINST the re-election of Messrs. Crowley and Kishbauch By voting AGAINST Mr. Crowley as
Slide 49: Velan’s Approach to Board Duties
Velan’s Approach to Board Duties Governance ― Instill culture of accountability, alignment, and analytical rigor ― Proper assessment of management based on performance relative to ambitious corporate goals ― Long-term, performance-based incentive plans, stock ownership requirements ― Scrutinize ma
Slide 50: Weighing Key Takeaways
Weighing Key Takeaways Compelling Value Proposition Accountability, management oversight and stockholder alignment tip the scale in favor of enduring success Velan Capital, L.P. – ALL RIGHTS RESERVED 50
Slide 51: Vote to Protect the Value of Your Investment on the GREEN Proxy Card
Vote to Protect the Value of Your Investment on the GREEN Proxy Card TODAY Vote AGAINST Messrs. Crowley and Kishbauch Given the Lack of Accountability and Stockholder Alignment, and Egregious Corporate Governance Practices Vote AGAINST the Compensation Proposal Given the Persistent Underperformance
Slide 52: Appendix
Appendix Velan Capital, L.P. – ALL RIGHTS RESERVED 52
Slide 53: Background to Velan’s Solicitation
Background to Velan’s Solicitation After having followed the Company and its predecessors for years, Velan initiated its current investment in July 2018 and initially interacted with representatives of the Company during a telephonic conversation on November 29, 2018. Over the ensuing months, Ve
Slide 54: Background to Velan’s Solicitation (Cont’d)
Background to Velan’s Solicitation (Cont’d) On March 27, 2019, the Participating Stockholders crossed the five percent (5%) ownership threshold, thereby triggering their obligation under the Securities Exchange Act of 1934 (the “Exchange Act”) to file a Schedule 13D within 10 calendar days. On A
Slide 55: Background to Velan’s Solicitation (Cont’d)
Background to Velan’s Solicitation (Cont’d) On April 24, 2019, Messrs. Venkataraman, Heck, Sarpangal and Cooke held separate in-person meetings in New York City with Mr. Kishbauch and Ms. Williams to discuss their respective qualifications for serving on the Board. During Mr. Venkataraman’s meetin
Slide 56: Velan: Proposed Nominees
Velan: Proposed Nominees Bala Venkataraman: Mr. Venkataraman is an experienced operating executive and investor in the specialty pharmaceutical industry and is currently a Partner at Avego Healthcare Capital, LLC. Since 2013, Mr. Venkataraman has launched, financially sponsored, and successfully bui
Slide 57: Velan: Proposed Nominees (Cont’d)
Velan: Proposed Nominees (Cont’d) Matthew Heck: Mr. Heck is the original founder, CEO and a member of the Board of Directors of Sentynl Therapeutics, Inc. and has 25 years of experience in the pharmaceutical industry. At Sentynl, he has been the key driver behind M&A, financing, hiring and managing
Slide 58: Velan: Proposed Nominees (Cont’d)
Velan: Proposed Nominees (Cont’d) Ryan Melkonian: Mr. Melkonian is the founder and managing partner of Melkonian Capital Management. With 25 years of investment experience, Ryan is responsible for overseeing the firm’s investment portfolio (private equity, real estate and public markets) and chairs
Progenics Pharmaceuticals — Proxy Contest (June 2019) on 6ix